Pelage Pharmaceuticals is a clinical-stage regenerative medicine company developing first-in-class treatments for hair loss. With a focus on stem cell biology and metabolism, Pelage is advancing a new class of treatments designed to reactivate dormant hair follicle stem cells and restore the body's ability to naturally grow hair. Its lead program, PP405, is currently in Phase 2a clinical trials. Through its rigorous scientific foundation, Pelage is pioneering first-in-class hair growth solutions for people of all hair types experiencing hair loss.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/15/25 | $120,000,000 | Series B |
ARCH Venture Partners GV Main Street Advisors Visionary Ventures Fund YK Bioventures | undisclosed |
